Ligand Executive Sells 5,000 Shares for $1.1 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: Yahoo Finance
- Transaction Overview: Andrew Reardon, CLO of Ligand, sold 5,000 shares of common stock for approximately $1.14 million on June 1, 2026, following the immediate exercise of stock options, indicating a liquidity event linked to long-term incentive awards.
- Holding Changes: Post-transaction, Reardon directly holds 41,382 shares and retains 39,444 employee stock options, maintaining alignment with investor interests, although the current sale represents 10.78% of his remaining holdings, the highest ratio in recent transactions.
- Market Performance: As of the transaction date, Ligand's stock achieved a total return of 123.61% over the past year, suggesting that this liquidity event capitalized on a period of strong share price appreciation, potentially providing a solid foundation for future capital operations.
- Business Growth: Ligand's drug licensing business saw a 56% year-over-year increase in royalty revenue to $43 million in Q1, despite a decline in Captisol sales; overall revenue still grew 14% year-over-year to $51.7 million, highlighting the company's robust growth potential in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 235.910
Low
220.00
Averages
237.20
High
270.00
Current: 235.910
Low
220.00
Averages
237.20
High
270.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ligand Executive Sells $1.14 Million in Stock Following Options Exercise
- Executive Stock Sale: Ligand's CLO Andrew Reardon sold 5,000 shares of common stock for approximately $1.14 million on June 1, 2026, reflecting an immediate disposition tied to the exercise of long-term incentive awards, indicating executive confidence in the company's stock price appreciation.
- Ownership Analysis: Post-transaction, Reardon directly holds 41,382 shares and retains 39,444 employee stock options, demonstrating alignment with investor interests and potential for future equity sales as additional options vest.
- Market Performance Review: As of the transaction date, Ligand delivered a total return of 123.61% over the past year, with the timing of this sale coinciding with strong stock price appreciation, highlighting the executive's strategic liquidity event.
- Growth Potential: Ligand's drug licensing business is experiencing rapid growth, with first-quarter royalty revenue surging 56% year-over-year to $43 million, despite a decline in Captisol sales, indicating robust momentum in the biopharmaceutical sector.
See More
Ligand Executive Sells Shares to Supplement Income
- Share Sale Overview: Andrew Reardon sold 5,000 shares of Common Stock on June 1, 2026, for approximately $1.14 million at a weighted average price of $227.06 per share, reducing his direct holdings to 41,382 shares, indicating an executive's intent to supplement income rather than exit a poor investment.
- Options Exercise Details: The transaction involved the immediate exercise and sale of stock options, with Reardon holding no indirect shares post-transaction while retaining 39,444 employee stock options, suggesting ongoing liquidity potential to support future company growth.
- Revenue Growth and Challenges: Ligand's first-quarter royalty revenue surged 56% year-over-year to $43 million, although sales of its drug solubility enhancer, Captisol, fell from $13.5 million to $8.7 million, reflecting the impact of customer order timing on revenue.
- Strategic Positioning: Ligand focuses on biotechnology platforms and royalty-driven partnerships with pharmaceutical manufacturers, leveraging high-margin licensing and royalties to solidify its key role in the biopharmaceutical sector, with future growth potential bolstered by recent drug approvals.
See More
Ligand Executive Sells 5,000 Shares for $1.1 Million
- Transaction Overview: Andrew Reardon, CLO of Ligand, sold 5,000 shares of common stock for approximately $1.14 million on June 1, 2026, following the immediate exercise of stock options, indicating a liquidity event linked to long-term incentive awards.
- Holding Changes: Post-transaction, Reardon directly holds 41,382 shares and retains 39,444 employee stock options, maintaining alignment with investor interests, although the current sale represents 10.78% of his remaining holdings, the highest ratio in recent transactions.
- Market Performance: As of the transaction date, Ligand's stock achieved a total return of 123.61% over the past year, suggesting that this liquidity event capitalized on a period of strong share price appreciation, potentially providing a solid foundation for future capital operations.
- Business Growth: Ligand's drug licensing business saw a 56% year-over-year increase in royalty revenue to $43 million in Q1, despite a decline in Captisol sales; overall revenue still grew 14% year-over-year to $51.7 million, highlighting the company's robust growth potential in the biopharmaceutical sector.
See More
Legend Biotech Reports Promising Early Results for LB2501 CAR-T Therapy
- Clinical Trial Results: Legend Biotech announced that LB2501 achieved a 100% objective response rate in early trials, with an approximately 84% complete response rate, indicating significant potential in treating B-cell non-Hodgkin lymphoma, which could enhance the company's market share in this area.
- Therapeutic Advantage: The in vivo generation method of LB2501 simplifies manufacturing and administration compared to traditional ex vivo CAR-T therapies, which is expected to lower treatment costs and improve patient acceptance, thereby strengthening the company's competitive position.
- Safety Assessment: The trial results indicated no dose-limiting toxicities, serious adverse events, or deaths, although nearly 70% of patients experienced cytokine release syndrome at Grade 2 or below, providing positive support for the therapy's safety and potentially attracting more investor interest.
- Academic Presentation Opportunity: The trial results will be presented at the 2026 European Hematology Association Congress, further enhancing Legend Biotech's visibility in the academic community and potentially facilitating future collaborations and investment opportunities.
See More
Ligand Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Release Date: Ligand Pharmaceuticals is set to announce its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at $1.80 and revenue at $58.86 million, reflecting a 29.9% year-over-year growth, which could significantly impact the stock price.
- Performance Beat Record: Over the past two years, Ligand has exceeded EPS estimates 88% of the time and revenue estimates 100% of the time, demonstrating strong performance in profitability and market expectation management.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates experienced three upward and one downward revision, indicating market divergence and adjustments regarding the company's future performance.
- Acquisition Activity: Ligand Pharmaceuticals plans to acquire XOMA Royalty for $39 per share in a $740 million all-cash deal, which will further enhance the company's market position and revenue streams.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Ligand Executive Sells $1.14 Million in Stock Following Options Exercise
- Executive Stock Sale: Ligand's CLO Andrew Reardon sold 5,000 shares of common stock for approximately $1.14 million on June 1, 2026, reflecting an immediate disposition tied to the exercise of long-term incentive awards, indicating executive confidence in the company's stock price appreciation.
- Ownership Analysis: Post-transaction, Reardon directly holds 41,382 shares and retains 39,444 employee stock options, demonstrating alignment with investor interests and potential for future equity sales as additional options vest.
- Market Performance Review: As of the transaction date, Ligand delivered a total return of 123.61% over the past year, with the timing of this sale coinciding with strong stock price appreciation, highlighting the executive's strategic liquidity event.
- Growth Potential: Ligand's drug licensing business is experiencing rapid growth, with first-quarter royalty revenue surging 56% year-over-year to $43 million, despite a decline in Captisol sales, indicating robust momentum in the biopharmaceutical sector.
See More
Ligand Executive Sells Shares to Supplement Income
- Share Sale Overview: Andrew Reardon sold 5,000 shares of Common Stock on June 1, 2026, for approximately $1.14 million at a weighted average price of $227.06 per share, reducing his direct holdings to 41,382 shares, indicating an executive's intent to supplement income rather than exit a poor investment.
- Options Exercise Details: The transaction involved the immediate exercise and sale of stock options, with Reardon holding no indirect shares post-transaction while retaining 39,444 employee stock options, suggesting ongoing liquidity potential to support future company growth.
- Revenue Growth and Challenges: Ligand's first-quarter royalty revenue surged 56% year-over-year to $43 million, although sales of its drug solubility enhancer, Captisol, fell from $13.5 million to $8.7 million, reflecting the impact of customer order timing on revenue.
- Strategic Positioning: Ligand focuses on biotechnology platforms and royalty-driven partnerships with pharmaceutical manufacturers, leveraging high-margin licensing and royalties to solidify its key role in the biopharmaceutical sector, with future growth potential bolstered by recent drug approvals.
See More
Ligand Executive Sells 5,000 Shares for $1.1 Million
- Transaction Overview: Andrew Reardon, CLO of Ligand, sold 5,000 shares of common stock for approximately $1.14 million on June 1, 2026, following the immediate exercise of stock options, indicating a liquidity event linked to long-term incentive awards.
- Holding Changes: Post-transaction, Reardon directly holds 41,382 shares and retains 39,444 employee stock options, maintaining alignment with investor interests, although the current sale represents 10.78% of his remaining holdings, the highest ratio in recent transactions.
- Market Performance: As of the transaction date, Ligand's stock achieved a total return of 123.61% over the past year, suggesting that this liquidity event capitalized on a period of strong share price appreciation, potentially providing a solid foundation for future capital operations.
- Business Growth: Ligand's drug licensing business saw a 56% year-over-year increase in royalty revenue to $43 million in Q1, despite a decline in Captisol sales; overall revenue still grew 14% year-over-year to $51.7 million, highlighting the company's robust growth potential in the biopharmaceutical sector.
See More
Legend Biotech Reports Promising Early Results for LB2501 CAR-T Therapy
- Clinical Trial Results: Legend Biotech announced that LB2501 achieved a 100% objective response rate in early trials, with an approximately 84% complete response rate, indicating significant potential in treating B-cell non-Hodgkin lymphoma, which could enhance the company's market share in this area.
- Therapeutic Advantage: The in vivo generation method of LB2501 simplifies manufacturing and administration compared to traditional ex vivo CAR-T therapies, which is expected to lower treatment costs and improve patient acceptance, thereby strengthening the company's competitive position.
- Safety Assessment: The trial results indicated no dose-limiting toxicities, serious adverse events, or deaths, although nearly 70% of patients experienced cytokine release syndrome at Grade 2 or below, providing positive support for the therapy's safety and potentially attracting more investor interest.
- Academic Presentation Opportunity: The trial results will be presented at the 2026 European Hematology Association Congress, further enhancing Legend Biotech's visibility in the academic community and potentially facilitating future collaborations and investment opportunities.
See More
Ligand Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Release Date: Ligand Pharmaceuticals is set to announce its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at $1.80 and revenue at $58.86 million, reflecting a 29.9% year-over-year growth, which could significantly impact the stock price.
- Performance Beat Record: Over the past two years, Ligand has exceeded EPS estimates 88% of the time and revenue estimates 100% of the time, demonstrating strong performance in profitability and market expectation management.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates experienced three upward and one downward revision, indicating market divergence and adjustments regarding the company's future performance.
- Acquisition Activity: Ligand Pharmaceuticals plans to acquire XOMA Royalty for $39 per share in a $740 million all-cash deal, which will further enhance the company's market position and revenue streams.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
